Key Drivers
- Strong Liquidity
- Persistent Losses
- Rising Leverage
AIAI Summary
TEM has moved beyond a pure AI-healthcare story into a more credible commercial platform with FDA validation, MRD growth, and partnerships, but the breakout already prices in success while widening losses, negative free cash flow, and rising leverage make it a neutral hold until revenue growth clearly outruns expenses and cash burn narrows.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Rising Leverage
TEM shows strong liquidity and healthy gross margins, but persistent losses, cash burn, and rising leverage keep the risk profile elevated.
Price Behavior
Key Price Behavior Insights:
- •Breakout momentum
- •Higher-lows trend
- •Stretched near highs
TEM has turned from a choppy base into a strong uptrend over the last month, with a breakout to $61.60, but it is now stretched and may need to cool off before extending higher.
Breakout accelerated from 2026-06-24 to 2026-07-01, signaling strong short-term momentum
Sentiment & News
Key News Insights:
- •Data moat growth
- •FDA expansion
- •Losses volatility
Tempus AI showed strong diagnostics, data, and FDA-driven product momentum in June, but ongoing GAAP losses and execution risk keep the stock volatile.
The news supports Tempus AI's long-term growth story, but near-term upside may stay capped by profitability concerns and execution uncertainty
Similar Companies in Healthcare
Other companies in the same sector with AI ratings